About - BIAF :

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

Employees - 75, CEO - Ms. Maria Zannes J.D., Sector - Healthcare, Country - US, Market Cap - 15.47M

Altman ZScore(max is 10): -10.89, Piotroski Score(max is 10): 2, Working Capital: $57974, Total Assets: $6552014, Retained Earnings: $-50677413, EBIT: -8336842, Total Liabilities: $3430989, Revenue: $9367785

AryaFin Target Price - $0.13 - Current Price $0.99 - Analyst Target Price $6.00

Stats & Key Metrics
TickerBIAF
Index-
Curent Price 0.99
Change-15.86%
Market Cap15.47M
Average Volume145.52K
Income-8.45M
Sales9.37M
Book Value/Share0.23
Cash/Share0.05
Dividend Est-
Dividend TTM-
Dividend Ex-Date-
Employees75
Moving Avg 20days-7.16%
Moving Avg 50days-23.83%
Moving Avg 200days-48.19%
Shares Outstanding13.42M
Earnings DateNov 14 BMO
Inst. Ownership3.00%
Key Ratios & Margins
Price/Earnings-
Forwad P/E-
PE Growth-
Price/Sales1.65
Price/Book4.27
Price/Cash20.35
Price/FCF-
Quick Ratio1.01
Current Ratio1.02
Debt/Equity0.55
Return on Assets-100.90%
Return on Equity-167.00%
Return on Investment-207.99%
Gross Margin28.62%
Ops Margin-89.13%
Profit Margin-90.16%
RSI41.69
BETA(β)2.94
From 52week Low19.54%
From 52week High-72.57%
Earnings & Valuation
EPS-0.80
EPS next Year-0.66
EPS next Qtr-0.14
EPS this Year24.18%
EPS next 5 Year-
EPS past 5 Year-19.28%
Sales past 5 Year13156.86%
EPS Y/Y5.64%
Sales Y/Y2813.87%
EPS Q/Q38.69%
Sales Q/Q687.44%
Sales Surprise-7.43%
EPS Surprise-6.67%
ATR(14)0.13
Perf Week6.75%
Perf Month-21.83%
Perf Quarter-49.35%
Perf Year-37.56%
Perf YTD-32.49%
Target Price6.00

AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer